

---

## Bevacizumab, sorafenib tosylate and sunitinib for renal cell carcinoma: a systematic review and economic evaluation

*Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K*

---

### Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

### Citation

Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K. Bevacizumab, sorafenib tosylate and sunitinib for renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment 2010; 14(2): 1-207

### Authors' conclusions

Study found that bevacizumab, combined with interferon, and sunitinib have clinically relevant advantages over interferon alone in patients with metastatic renal cell carcinoma, temsirolimus has clinically relevant advantages over interferon in those with poor prognosis, and sorafenib tosylate is superior to best supportive care as second-line therapy, although none of the treatments was considered cost-effective at normal willingness to pay thresholds.

### Project page URL

<http://www.hta.ac.uk/1711>

### URL for DARE abstract

<http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=12010001018& amp;UserID=0>

### Link to NHS EED abstract

<http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=22010000214& amp;UserID=0>

### INAHTA brief and checklist

<http://www.inahta.org/Publications/Briefs-Checklist-Impact/2010/4629/?type=checknew>

[http://www.inahta.org/upload/Briefs\\_11/10132\\_NETSCC\\_Bevacizumab\\_Sorafenib\\_Tosylate\\_Sunitinib\\_Renal\\_Cell\\_Carcinoma\\_A\\_Systematic\\_Review\\_Economic\\_Evaluation.pdf](http://www.inahta.org/upload/Briefs_11/10132_NETSCC_Bevacizumab_Sorafenib_Tosylate_Sunitinib_Renal_Cell_Carcinoma_A_Systematic_Review_Economic_Evaluation.pdf)

### Indexing Status

Subject indexing assigned by CRD

### MeSH

Angiogenesis Inhibitors /therapeutic use; Antineoplastic Agents /therapeutic use; Carcinoma, Renal Cell /drug therapys

### Language Published

English

### Country of organisation

England

### Address for correspondence

NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: [hta@hta.ac.uk](mailto:hta@hta.ac.uk)

### AccessionNumber

32010000102

**Date abstract record published**

27/01/2010